Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study

L. Davis,A. Ota,P. Perry,K. Tsuneyoshi,E. Weiller,R. Baker
DOI: https://doi.org/10.1002/brb3.520
IF: 3.1
2016-07-24
Brain and Behavior
Abstract:Major depressive disorder (MDD) with concurrent anxiety symptoms may signal a difficult‐to‐treat patient. Brexpiprazole is a serotonin–dopamine activity modulator: a partial agonist at 5‐HT1A and dopamine D2 receptors at similar potency, and an antagonist at 5‐HT2A and noradrenaline alpha1B/2C receptors. The objective of this Phase IIIb study was to explore effectiveness, safety, and tolerability of brexpiprazole adjunctive to antidepressant (ADT) monotherapy in patients with MDD and anxiety symptoms (NCT02013531).
What problem does this paper attempt to address?